Comparison	comparison	O	O
of	of	O	O
the	the	O	O
effectiveness	effectiveness	O	O
of	of	O	O
ranitidine	ranitidine	S_chemicals	O
and	and	O	O
cimetidine	cimetidine	S_chemicals	O
in	in	O	O
inhibiting	inhibiting	O	O
acid	acid	S_chemicals	O
secretion	secretion	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
gastric	gastric	O	O
hypersecretory	hypersecretory	O	O
states	states	O	O
.	.	O	O

The	the	O	O
H2-histamine	h2-histamine	O	O
receptor	receptor	B_chemicals	O
antagonists	antagonists	I_chemicals	O
ranitidine	ranitidine	S_chemicals	O
and	and	O	O
cimetidine	cimetidine	S_chemicals	O
were	were	O	O
compared	compared	O	O
for	for	O	O
their	their	O	O
abilities	abilities	O	O
to	to	O	O
control	control	O	O
gastric	gastric	O	B_disease
acid	acid	S_chemicals	I_disease
hypersecretion	hypersecretion	O	O
on	on	O	O
a	a	O	O
short-	short-	O	O
and	and	O	O
long-term	long-term	O	O
basis	basis	O	O
in	in	O	O
22	22	O	O
patients	patients	O	O
with	with	O	O
gastric	gastric	O	B_disease
acid	acid	S_chemicals	I_disease
hypersecretory	hypersecretory	O	O
states	states	O	O
.	.	O	O

Nineteen	nineteen	O	O
patients	patients	O	O
had	had	O	O
Zollinger-Ellison	zollinger-ellison	O	B_disease
syndrome	syndrome	O	S_disease
,	,	O	O
one	one	O	O
patient	patient	O	O
had	had	O	O
systemic	systemic	O	B_disease
mastocytosis	mastocytosis	O	S_disease
,	,	O	O
and	and	O	O
two	two	O	O
patients	patients	O	O
had	had	O	O
idiopathic	idiopathic	O	O
hypersecretion	hypersecretion	O	O
.	.	O	O

The	the	O	O
rates	rates	O	O
of	of	O	O
onset	onset	O	O
of	of	O	O
the	the	O	O
action	action	O	O
of	of	O	O
cimetidine	cimetidine	S_chemicals	O
and	and	O	O
ranitidine	ranitidine	S_chemicals	O
were	were	O	O
the	the	O	O
same	same	O	O
.	.	O	O

The	the	O	O
actions	actions	O	O
of	of	O	O
both	both	O	O
drugs	drugs	S_chemicals	O
were	were	O	O
increased	increased	O	O
by	by	O	O
anticholinergic	anticholinergic	B_chemicals	O
agents	agents	I_chemicals	O
,	,	O	O
and	and	O	O
there	there	O	O
was	was	O	O
a	a	O	O
close	close	O	O
correlation	correlation	O	O
between	between	O	O
the	the	O	O
daily	daily	O	O
maintenance	maintenance	O	O
dose	dose	O	O
of	of	O	O
each	each	O	O
drug	drug	S_chemicals	O
needed	needed	O	O
to	to	O	O
control	control	O	O
acid	acid	S_chemicals	O
secretion	secretion	O	O
.	.	O	O

However	however	O	O
,	,	O	O
ranitidine	ranitidine	S_chemicals	O
was	was	O	O
threefold	threefold	O	O
more	more	O	O
potent	potent	O	O
than	than	O	O
cimetidine	cimetidine	S_chemicals	O
both	both	O	O
in	in	O	O
acute	acute	O	O
inhibition	inhibition	O	O
studies	studies	O	O
and	and	O	O
in	in	O	O
the	the	O	O
median	median	O	O
maintenance	maintenance	O	O
dose	dose	O	O
needed	needed	O	O
(	(	O	O
1.2	1.2	O	O
g	g	O	O
per	per	O	O
day	day	O	O
for	for	O	O
ranitidine	ranitidine	S_chemicals	O
and	and	O	O
3.6	3.6	O	O
g	g	O	O
per	per	O	O
day	day	O	O
for	for	O	O
cimetidine	cimetidine	S_chemicals	O
)	)	O	O
.	.	O	O

Sixty	sixty	O	O
percent	percent	O	O
of	of	O	O
the	the	O	O
males	males	O	O
developed	developed	O	O
breast	breast	O	O
changes	changes	O	O
or	or	O	O
impotence	impotence	O	S_disease
while	while	O	O
taking	taking	O	O
cimetidine	cimetidine	S_chemicals	O
and	and	O	O
in	in	O	O
all	all	O	O
cases	cases	O	O
these	these	O	O
changes	changes	O	O
disappeared	disappeared	O	O
when	when	O	O
cimetidine	cimetidine	S_chemicals	O
was	was	O	O
replaced	replaced	O	O
by	by	O	O
ranitidine	ranitidine	S_chemicals	O
.	.	O	O

Treatment	treatment	O	O
with	with	O	O
high	high	O	O
doses	doses	O	O
of	of	O	O
cimetidine	cimetidine	S_chemicals	O
(	(	O	O
one	one	O	O
to	to	O	O
60	60	O	O
months	months	O	O
;	;	O	O
median	median	O	O
,	,	O	O
11	11	O	O
months	months	O	O
)	)	O	O
or	or	O	O
ranitidine	ranitidine	S_chemicals	O
(	(	O	O
two	two	O	O
to	to	O	O
31	31	O	O
months	months	O	O
;	;	O	O
median	median	O	O
,	,	O	O
14	14	O	O
months	months	O	O
)	)	O	O
was	was	O	O
not	not	O	O
associated	associated	O	O
with	with	O	O
hepatic	hepatic	O	O
or	or	O	O
hematologic	hematologic	O	O
toxicity	toxicity	O	O
or	or	O	O
alterations	alterations	O	O
of	of	O	O
serum	serum	O	O
gastrin	gastrin	O	O
concentrations	concentrations	O	O
,	,	O	O
but	but	O	O
ranitidine	ranitidine	S_chemicals	O
therapy	therapy	O	O
was	was	O	O
associated	associated	O	O
with	with	O	O
a	a	O	O
significantly	significantly	O	O
lower	lower	O	O
serum	serum	O	O
creatinine	creatinine	S_chemicals	O
level	level	O	O
than	than	O	O
seen	seen	O	O
with	with	O	O
cimetidine	cimetidine	S_chemicals	O
therapy	therapy	O	O
.	.	O	O

The	the	O	O
results	results	O	O
show	show	O	O
that	that	O	O
both	both	O	O
drugs	drugs	S_chemicals	O
can	can	O	O
adequately	adequately	O	O
inhibit	inhibit	O	O
acid	acid	S_chemicals	O
secretion	secretion	O	O
in	in	O	O
patients	patients	O	O
with	with	O	O
gastric	gastric	O	O
hypersecretory	hypersecretory	O	O
states	states	O	O
.	.	O	O

Both	both	O	O
are	are	O	O
safe	safe	O	O
at	at	O	O
high	high	O	O
doses	doses	O	O
,	,	O	O
but	but	O	O
ranitidine	ranitidine	S_chemicals	O
is	is	O	O
threefold	threefold	O	O
more	more	O	O
potent	potent	O	O
and	and	O	O
does	does	O	O
not	not	O	O
cause	cause	O	O
the	the	O	O
antiandrogen	antiandrogen	S_chemicals	O
side	side	O	B_disease
effects	effects	O	I_disease
frequently	frequently	O	O
seen	seen	O	O
with	with	O	O
high	high	O	O
doses	doses	O	O
of	of	O	O
cimetidine	cimetidine	S_chemicals	O
.	.	O	O

